Not logged in...
About USC Norris
Research
Patient Care
CISO
Search Trials
FAQ - Trials
Contact Us - Trials
Membership
Education
Shared Resources
Support USC Norris
Outreach
Login/Logout
Contact USC Norris
Support Us
Donate
Menu
USC Norris
»
Clinical Trials
Trial 0S-14-6
Phase I Open Label, Multi-center, Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered CUDC-907, a PI3K and HDAC Inhibitor, in Subjects with Refractory or Relapsed Lymphoma or Multiple Myeloma
Type:
Treatment
Phase:
Phase I
Status:
Not Open (Closed)
Treatments:
Chemotherapy: Systemic
Randomized:
No
USC Satellite Location:
None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:
Kevin Kelly, M.D.
Other Trial Staff:
Christine Duran, Coordinator, Ibrahim Syed, Coordinator, Melissa Peralta, D.M., Niranjan Bhatt, D.M., Anastasia Martynova, D.M.
Staff may
log in
to see study documents.
Click here to see trial eligibility criteria and further details at ClinicalTrials.gov
For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or
clinical.trials@med.usc.edu
.
To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.